Long noncoding RNAs in neuronal-glial fate specification and oligodendrocyte lineage maturation by Mercer, Tim R. et al.
RESEARCH ARTICLE Open Access
Long noncoding RNAs in neuronal-glial fate
specification and oligodendrocyte lineage
maturation
Tim R Mercer1†, Irfan A Qureshi2,3,6†, Solen Gokhan2,3,6, Marcel E Dinger1, Guangyu Li3,6, John S Mattick1*,
Mark F Mehler2,3,4,5,6*
Abstract
Background: Long non-protein-coding RNAs (ncRNAs) are emerging as important regulators of cellular
differentiation and are widely expressed in the brain.
Results: Here we show that many long ncRNAs exhibit dynamic expression patterns during neuronal and
oligodendrocyte (OL) lineage specification, neuronal-glial fate transitions, and progressive stages of OL lineage
elaboration including myelination. Consideration of the genomic context of these dynamically regulated ncRNAs
showed they were part of complex transcriptional loci that encompass key neural developmental protein-coding
genes, with which they exhibit concordant expression profiles as indicated by both microarray and in situ
hybridization analyses. These included ncRNAs associated with differentiation-specific nuclear subdomains such as
Gomafu and Neat1, and ncRNAs associated with developmental enhancers and genes encoding important
transcription factors and homeotic proteins. We also observed changes in ncRNA expression profiles in response to
treatment with trichostatin A, a histone deacetylase inhibitor that prevents the progression of OL progenitors into
post-mitotic OLs by altering lineage-specific gene expression programs.
Conclusion: This is the first report of long ncRNA expression in neuronal and glial cell differentiation and of the
modulation of ncRNA expression by modification of chromatin architecture. These observations explicitly link
ncRNA dynamics to neural stem cell fate decisions, specification and epigenetic reprogramming and may have
important implications for understanding and treating neuropsychiatric diseases.
Background
It has recently become evident that the majority of the
mammalian genome is transcribed in a developmentally
regulated manner producing tens of thousands of inter-
leaved short and long ncRNAs [1-4]. Long ncRNAs,
defined as greater than 200 nt in length [5], exhibit spe-
cific temporal and spatial expression patterns in mouse
brain [6], embryonic stem cell differentiation [7] and T-
cell differentiation [8]. NcRNAs are also implicated in
neural developmental events and in the pathogenesis of
neuropsychiatric diseases [9]. These long ncRNAs are
being shown to have a wide range of functions, includ-
ing roles in the regulation of chromosomal architecture
and dynamics, transcription, post-transcriptional proces-
sing, RNA editing, RNA trafficking and organelle bio-
genesis [4,10-14]. One major emergent function of long
ncRNAs is their ability to modulate the epigenetic status
of nearby protein-coding genes by recruiting chromatin
activator or repressor complexes [4,12,15].
Here we present the first systematic examination of
long ncRNA expression profiles during differentiation of
embryonic forebrain-derived neural stem cells (NSCs).
We focused on a subset of cortical GABAergic neurons
(GABANs) and oligodendrocytes (OLs) that are initially
specified from sonic hedgehog (Shh)-responsive, Nkx2.1-
expressing bipotent neuronal-OL progenitor (N/OP) spe-
cies within the ventromedial forebrain. We have pre-
viously reported that these N/OPs undergo long-distance
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tangential migration to cerebral cortex where they
sequentially give rise to GABANs and OLs [16-21]. We
employed custom designed microarrays to examine
expression of noncoding and protein-coding transcripts
during these neural developmental transitions, finding
dynamic expression of ncRNAs associated with key
neural development genes. We also observed differential
expression of specific ncRNAs after treatment of oligo-
dendrocyte progenitors (OLPs) with trichostatin A (TSA),
a histone deacetylase (HDAC) inhibitor that prevents
progression of OLPs into post-mitotic oligodendrocytes
(PMOs) by suppressing oligodendrocyte-specific genes
and inducing epigenetic reprogramming [22-26]. These
developmental changes underscore the importance of epi-
genetic regulation in the elaboration of neural cell types
and imply functional relationships between chromatin
remodeling and selective deployment of ncRNAs.
Results
We conducted gene expression profiling using a custom-
designed microarray platform to examine protein-coding
and noncoding transcript expression accompanying
neural stem cell-mediated fate restriction (bipotent pro-
genitor cells: N/OPs), neural lineage specification
(GABAergic neurons: GABANs and oligodendrocyte pro-
genitors: OLPs), neuronal-glial fate switching (GABANs
® OLPs), and neural lineage maturation (post-mitotic
oligodendrocytes: PMOs and myelinating oligodendro-
cytes: MYOs) (Figure 1). In total, we found 31% (4,616
out of 14,827) of probes targeting protein-coding tran-
scripts exhibited expression above background and that
2366 (16%) of these were significantly differentially
expressed (B-statistic > 1) at one or more developmental
stages compared to NSCs [Additional file 1].
We found that 9% (332 out of 3,659) of probes targeting
ncRNAs were expressed above background, of which 169
(5%) were significantly differentially expressed (B-statistic
> 1; Figure 1) at one or more developmental stages com-
pared to the NSC control [Additional file 2). These data
reveal that a smaller percentage of ncRNAs are differen-
tially expressed relative to protein-coding mRNAs. While
this difference may be due to relatively poor annotation of
the long noncoding transcriptome, it is consistent with
previous reports in other developmental models [1,27]
and may reflect the fact that ncRNAs are primarily regula-
tory in nature requiring only subtle changes in expression
to carry out their functional roles [28]. We also validated
our microarray findings with QRT-PCR and found an 87%
correlation between the gene expression profiles from the
microarray data and QRT-PCR results [Additional file 3].
Genomic analysis of expressed ncRNAs
Long ncRNAs are often organized as part of complex
interleaved transcriptional networks that include protein-
coding genes [1,2]. A number of studies have shown that
the association of long noncoding transcription with pro-
tein-coding genes has functional relevance, often with the
ncRNA regulating expression of its protein-coding coun-
terpart via epigenetic modifications and/or transcriptional
co-activation/repression [14,15,29-31]. Therefore, we
identified all ncRNAs expressed in our developmental
models that are transcribed antisense to, bi-directionally,
or from within the introns of overlapping or adjacent
protein coding genes [Additional file 4]. In addition, we
identified pairs of protein-coding RNAs and ncRNAs
whose genomic loci are positionally conserved between
mouse and human [Additional file 4] because this geno-
mic conservation may also indicate a functional relation-
ship between the two transcripts. In many cases, the
associated protein-coding genes were critical neuro-devel-
opmental genes. As an illustrative example, the downre-
gulation of a ncRNA (AK053922) is associated with the
Gli3 locus in all progeny of N/OPs, whereas Gli3 was
upregulated in N/OPs but downregulated in all progeny
of N/OPs. This relationship may be of significant interest
given that Gli3 has been shown to act as a bifunctional
transcriptional switch that can either repress or activate
Shh signaling [32] to help specify distinct neuronal cell
types [33].
Many ncRNAs contain conserved secondary structures
that are crucial to their function [34]. These conforma-
tional features may be bound by proteins [35], processed
into smaller regulatory ncRNAs [36] or even fulfill
intrinsic catalytic functions [37]. To provide support for
the proposed functionality of the expressed ncRNAs, we
looked for evidence of RNA secondary structures within
differentially expressed ncRNA transcripts using the
folding program RNAz [34]. We found 74 expressed
ncRNAs that contained high confidence predicted con-
served secondary structures (RNAz P > 0.9) [Additional
file 5] such as stem-loops [Additional file 6], known to
be present in miRNA precursors, small nucleolar RNAs
(snoRNAs) and other RNAs with previously character-
ized functions.
We then combined these genomic analyses to identify
candidate ncRNAs for further functional analysis. These
are discussed in more detail below in the context of
neuronal and oligodendroglial lineage commitment, neu-
ronal-glial lineage switching and progressive stages of
oligodendrocyte lineage elaboration.
Lineage restriction of neural stem cells (NSCs) into
bipotent neuronal/oligodendrocyte progenitors (N/OPs)
A subset of nestin-immunoreactive NSCs within the
ventral forebrain give rise to bipotent N/OPs following
exposure to a gradient of Shh signaling [17,20] which
are characterized by expression of two bHLH transcrip-
tion factors (Olig2 and Mash1) and their potential to
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Figure 1 Profiles of gene expression during neural stem cell-mediated neural lineage elaboration. (A) Immunofluorescence micrographs
of cellular expression patterns of lineage markers and bHLH transcription factors during progressive GABAergic neuronal and OL lineage
elaboration from N/OPs: NSCs are labeled with nestin (TRITC) only, while N/OPs (white arrows) express both Olig2 (FITC, green arrow head) and
Mash 1 (TRITC, red arrow head). GABANs expressed GABA (FITC). OLPs are stained with O4 (FITC), while PMOs and MYOs are identified by the
expression of GC/O1 (FITC) and MBP (FITC), respectively. (B) Schematic flowchart illustrating the stages of oligodendrocyte and GABAergic
neuron lineages analyzed within this study. (C) Tree-plot showing expressed ncRNAs clustered according to differential expression during
microarray analysis. (D) Expression of mRNA marker genes with well characterized roles in GABAergic neuronal and progressive stages of OL
lineage elaboration as determined by microarray.
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give rise to GABANs and OLs but not astrocytes
[16,20]. Our microarray analysis revealed that the initial
fate restriction of regional forebrain NSCs to bipotent
N/OPs was associated with relatively modest changes in
gene expression profiles, possibly reflecting the relative
similarities between these developmental cell types.
Nonetheless, there were differences in factors that may
be important for promoting NSC lineage restriction and
abrogating self-renewal and maintenance programs,
including 65 upregulated and 167 downregulated
mRNAs [Additional file 1]. Not surprisingly, some genes
previously implicated in neurogenesis and gliogenesis
exhibited dynamic changes in mRNA expression includ-
ing transcription factors (52% of upregulated genes; p <
0.01) and cell-surface receptor linked signal transduction
pathways (21% of downregulated genes; p < 0.01). For
example, we found upregulated mRNAs included genes
such as Mash1, an important transcription factor that
promotes lineage restriction of NSCs into N/OPs
[38-40].
We also identified dynamically expressed ncRNAs that
may fulfill functional roles in NSC fate restriction. Simi-
lar to mRNAs, relatively few changes in ncRNA expres-
sion were observed during the transition from NSCs to
N/OPs, with 17 ncRNAs exhibiting differential expres-
sion (8 upregulated and 9 downregulated) [Additional
file 2]. These included a previously described ncRNA,
Gomafu, shown to be localized to a novel subnuclear
domain in a distinct subset of differentiating neurons in
the mouse nervous system [41], which was exclusively
downregulated in N/OPs but upregulated in all subse-
quent stages of OL lineage specification and maturation
[Additional file 7]. Furthermore, in situ hybridization
(ISH) in the adult mouse brain showed Gomafu expres-
sion in specific neuronal populations and nuclear locali-
zation within Purkinje cells [Additional file 7]. Our
results show that Gomafu is not only expressed during
neurogenesis but also during OL lineage specification.
A number of ncRNAs are significantly upregulated
only during lineage restriction of NSCs, including the
small nucleolar RNA (snoRNA) host gene 1 (Snhg1) and
10 (Snhg10), an expression profile supported by the
restricted neuronal expression of Snhg10 in whole brain
ISH [Additional file 8]. Snhg1 and Snhg10 host a group
of C/D box snoRNAs that serve as guides for the site-
specific 2’-O-methylation of ribosomal RNAs. Further-
more, two identified ncRNA species, Neat1 (also known
as Men ε/b) and Neat2, are downregulated in N/OPs
and broadly upregulated in their neuronal and glial pro-
geny (Figure 2). Neat1 and Neat2 associate with nuclear
paraspeckles and adjacent SC35 speckles, respectively;
domains where transcription and co-transcriptional pre-
mRNA processing occur [42]. These nuclear domains
have been associated with modulation of cell growth
and differentiation [43,44], and Neat1 (Men ε/b) has
been recently shown to be induced upon cell differentia-
tion and to be required for the structural integrity of
paraspeckles [45-47].
Specification of GABAergic neurons (GABANs)
Bipotent N/OPs can differentiate into either GABANs
or OLPs in response to different neural cytokines [20].
We therefore examined changes in gene expression dur-
ing the elaboration of GABANs to identify mRNAs and
ncRNAs that may be involved in this type of neuronal
lineage specification. We observed upregulation of 483
mRNAs, which were enriched for genes involved in ner-
vous system development (17.3%; p < 0.03), neuronal
function (9.88%, p < 0.05) and neurogenesis (10.67%, p
< 0.05). We also identified 330 downregulated mRNAs
[Additional file 1]. Interestingly, these downregulated
mRNAs were enriched for predicted targets of let-7b
(13.2% p < 0.01) and mir-135 (11.3%; p < 0.01), possibly
being subject to repression by miRNAs. Indeed, both
let-7b and mir-135 have previously been implicated in
promoting neurogenesis [48,49]. In addition, we identi-
fied 56 ncRNAs that are upregulated during GABAN
neurogenesis, including a number of examples such as
Gtl2, Rian, Evf2, and Copg2as that were previously
shown to exhibit neuron-enriched expression profiles in
the adult mouse brain [6]. In contrast, we identified
only 8 ncRNAs that were downregulated during
GABAergic neurogenesis [Additional file 2].
We distinguished ncRNAs that may be involved speci-
fically in GABAN lineage commitment by selecting
ncRNAs upregulated during GABAN differentiation but
downregulated during OL differentiation [Additional file
9]. We identified 4 ncRNAs, including an intergenic
ncRNA transcript AK044422 that overlaps a highly con-
served brain-specific miRNA, miR-124a. MiR-124a
accounts for nearly half of all brain miRNAs [50] (Figure
2) and helps to regulate neuronal specification and dif-
ferentiation [51-53]. One mechanism by which miR-124
was shown to promote neuronal differentiation is by
repression of Ptbp1, a negative regulator of alternative
splicing, resulting in activation of neuron-specific alter-
native splicing events [53]. Indeed, we found that Ptbp1
and AK044422 exhibited complementary expression pro-
files. However, the AK044422 transcript may itself func-
tion intrinsically as a full-length ncRNA, rather than
simply acting as a precursor. The AK044422 transcript
is subject to post-transcriptional modifications including
splicing and polyadenylation, contains a number of high
confidence predicted stem-loop structures (Fig 2.), and
is highly conserved with homologous transcripts present
in humans (AK091593, AL832535) and rats (BF402302).
Indeed, the AK044422 transcript was recently identified
in a genome wide screen for functional lncRNAs,
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termed lincRNAs, that exhibit a distinct chromatin sig-
nature indicative of transcriptional regulation and high
levels of expression [54]. Furthermore, ISH in adult
mouse brain revealed that the full-length AK044422
transcript is expressed in the mature central nervous
system (Figure 2), suggesting an involvement in neuro-
genesis independent of mir-124a.
Because a large number of developmental gene-related
enhancers have been shown to drive transcription in the
developing forebrain during early neurogenesis [55], we
examined ncRNAs expressed in GABANs that are asso-
ciated with highly conserved enhancers. We identified 3
ncRNAs that were associated with highly conserved ele-
ments driving transcription in the forebrain [Additional
file 10]. Two of these ncRNAs were associated with
ultraconserved enhancers at the Dlx genomic loci, one
of which, Evf-2, was previously shown to regulate bind-
ing of the Dlx2 transcription factor to the ultracon-
served enhancer to activate the expression of the
encompassed Dlx6 gene during neurogenesis [31].
We also identified a similar ncRNA antisense to the
Dlx1 gene. Both Dlx1 and the antisense ncRNA,
Dlx1AS, are upregulated during GABAN differentiation
but downregulated during OL differentiation [Additional
file 10]. These observations are consistent with pub-
lished data showing that Dlx1 and Dlx2 promote
GABAN lineage specification by suppressing the impor-
tant oligogenic bHLH transcription factor, Olig2 [56]
and are necessary for tangential migration of ventral
forebrain-derived progenitor cells [17,56-58]. Dlx1AS is
transcribed from an ultraconserved enhancer that drives
expression in the midbrain, forebrain and olfactory sys-
tem during development and in regions associated with
neurogenesis in the adult mouse brain [7]. The third
ncRNA, AK005755, which is also transcribed from an
ultraconserved enhancer driving expression in the devel-
oping forebrain, has not been previously described and
is not associated with any annotated developmental
genes. Nonetheless, expression of this spliced transcript
during GABAergic neurogenesis, coupled with its extre-
mely conserved enhancer, suggests it plays a role in the
developing forebrain.
Specification of oligodendrocyte progenitors (OLPs)
Application of PDGF-AA to N/OPs for 4 days in vitro
was sufficient to promote the elaboration of OLPs (Fig-
ure 1B). We confirmed by immunofluorescence micro-
scopy that N/OPs express the corresponding receptor
Figure 2 Detailed examples of ncRNAs expressed during oligodendrocyte differentiation. (A-F) Expression of the ncRNA AK044422 during
GABAN and OL differentiation. (A) Genomic context of the ncRNA AK044422 transcript (red), miR-124a (orange), RNA secondary structures as
predicted by RNAz [101] (green). (B-E) In situ hybridization of adult mouse brain sagittal sections for AK044422 transcript. (B) AK044422 is
expressed broadly throughout the adult mouse brain. (C) AK044422 exhibits an enriched expression in the Cornu Ammonis subfields (CA1-3; blue
arrow) (D) Detail of cerebellum shows AK044422 exhibits enriched expression in Purkinje neurons (green arrow). (E) Detail of olfactory bulb shows
enriched expression in the mitral layer (red arrow). Images courtesy of (Allen Brain Atlas, http://brain-map.com). (F) Example of RNA secondary
structure prediction within AK044422 transcript as rendered by CONTRAfold [99]. (G) Expression of AK044422 (red) and Ptbp1 (blue) according to
microarray analysis (expression is relative to NSCs and error bars show standard deviation). (H) Genomic context of Sox8 (blue) and ncRNA
Sox8OT transcript (AK070380; red). (I) Expression of Sox8OT (red) and Sox8 (blue) according to microarray analysis. (J) Genomic context of the
ncRNAs Neat1 (orange) and Neat2 (dark red) and histogram of vertebrate conservation (dark blue). (K) Expression of Neat1 (orange) and Neat2
(red) according to microarray analysis.
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(PDGFRa) expression prior to and independent of the
application of PDGF-AA [Additional file 11]. The devel-
opmental transition of N/OPs to OLs was associated
with the upregulation of 665 mRNAs including a num-
ber of OL-selective genes, such as Olig1 and Olig2, and
the downregulation of 650 mRNAs [Additional file 1].
We also found that 42 ncRNAs were downregulated,
whereas 58 ncRNAs were upregulated, six of which
exhibited highly correlated expression profiles to Olig1,
having a distinct peak during OLP differentiation (Pear-
sons R2 > 0.9) [Additional file 12; Additional file 13].
To identify ncRNAs with specific roles in OL lineage
commitment, we selected ncRNAs that were upregu-
lated in OLPs but downregulated in GABANs. This ana-
lysis identified only one ncRNA, a novel 1.2 kb
transcript (AK079380) organized bi-directionally to the
Sox8 gene (Figure 2). Sox8 is a member of the SRY-box
transcription factor family, many of which play key roles
in OL lineage elaboration, including Sox9 and Sox11 for
OL specification and Sox8 and Sox10 for progressive OL
maturation [59,60]. The ncRNA we identified, which we
termed Sox8OT (Sox8 Opposite Transcript), exhibited
concordant expression (Pearsons R2 > 0.9) to the Sox8
mRNA. Furthermore, a positionally conserved homolo-
gous Sox8OT transcript is also present in humans
(BC098409) and rats (BM382844), suggesting the bi-
directional relationship between Sox8 and Sox8OT is
relevant. The bidirectional organization of the Sox8 gene
and the Sox8OT ncRNA suggests that these transcripts
are subject to common modes of regulation, possibly by
sharing a promoter sequence. Indeed, recently published
genome-wide maps of chromatin modifications [61]
indicate a shared domain subject to dynamic modifica-
tions during the transition from embryonic stem to neu-
ronal progenitor cells [Additional file 14]. Together,
these data suggest Sox8OT functions in OL lineage com-
mitment, possibly by regulating the expression of the
associated Sox8 gene. As an alternative strategy to iden-
tify ncRNAs with specific roles in OL lineage commit-
ment, we identified ncRNAs that were differentially
expressed only in OLPs, and found that 16 were down-
regulated while 14 were upregulated including Dleu2, a
previously described ncRNA overlapping but transcribed
in the opposite direction of the Trim13 (RFP2/LEU5)
gene whose expression is upregulated during early OL
maturation and terminal differentiation [62].
Progressive stages of OL lineage maturation including
myelination
The withdrawal of OL cytokines (PDGF-AA) from OLP
culture conditions results in cell cycle exit (Figure 1A),
though the actions of environmental factors such as
triiodothyronine, cyclin dependent kinase inhibitors
(CDKIs: p27KIP1), inhibitory HLH transcription factors
(ID4) and other transcription factors (YY1) that partici-
pate in the combinatorial molecular programs regulating
this process [23,63-66]. In PMOs, we identified 768
upregulated mRNAs including genes involved in lipid
metabolic processes (11.4%, p < 0.02), such as Mbp, a
structural component of the myelin sheath [67]. We
also observed downregulation of 562 mRNAs including
genes involved in cell division (32.7%, p < 0.01), mitosis
(23.4%, p < 0.01), DNA replication (13.8%, p < 0.01),
and chromosome organization and biogenesis (8.65%, p
< 0.01). Similarly, OLP cell cycle exit was accompanied
by the upregulation of 38 ncRNAs and the downregula-
tion of 26 ncRNAs. Many of the ncRNAs are associated
with genomic loci encompassing protein-coding genes
with previously described functions in development and
maturation. For example, we found a highly conserved
ncRNA, AK019302, hosted within the intron of Bai3,
which was downregulated in PMOs. Bai3, which exhi-
bits a similar expression profile, is a developmentally
expressed angiostatic gene that is downregulated in the
early phases of brain ischemia and in high-grade gliomas
[68] and has been associated with mental retardation
[69] and schizophrenia [70].
OL terminal differentiation is associated with the out-
growth of cytoplasmic processes and the accelerated
production of myelin [71], and this process is regulated
by neural cytokines, various classes of transcription fac-
tors, CDKIs (p21CIP1), and epigenetic factors [72,73]. In
MYOs, we found 733 upregulated mRNAs that were
enriched for genes involved in lipid metabolic processes
(8.7%; p < 0.01), biopolymer metabolic processes (21.2%,
p < 0.01), and actin cytoskeleton organization (8.3%, p <
0.01), including a dramatic increase in the expression of
myelin genes such as Plp1, Mbp and Mal. In addition,
we found 51 ncRNAs that were upregulated during OL
terminal differentiation and myelination, including 8
that were broadly upregulated during progressive stages
of OL lineage elaboration, exhibiting a highly correlated
(Pearsons R2 > 0.9) [Additional file 9; Additional file 12]
expression profile with Mog, an important glycoprotein
found on the surface of MYOs [74]. In contrast, we
found that 35 ncRNAs were downregulated, including
27 ncRNAs that exhibited a highly correlated expression
profile (Pearsons R2 > 0.9) [Additional file 12; Additional
file 13] to Melk, a factor important for promoting NSC
proliferation [1,75] that was downregulated during OL
lineage elaboration.
A variety of ncRNAs were broadly upregulated in
OLPs, PMOs and MYOs including AK141895 and
AK133808, associated with the Slc44a1 and Rab11b
genomic loci, respectively. In these cases, both the
ncRNAs and the protein-coding transcripts were
strongly upregulated during OL lineage elaboration sug-
gesting that they may function coordinately to promote
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appropriate OL maturation and expression of myelin
proteins. We similarly identified a ncRNA antisense to
Ecsit, an important node between BMP and Toll-Like
Receptor (TLR) pathways that integrates morphogenetic
signaling with pathogen recognition and innate immu-
nity during development [76,77]. The ncRNA,
AK050588, is upregulated in GABANs, OLPs and
MYOs, in contrast to Ecsit, which is downregulated in
these species. The observed inverse expression pattern
between AK050588 and Ecsit is similar to a correlation
we recently observed in embryonic stem cell differentia-
tion [7] and suggests coordination between the expres-
sion profiles of this pair of transcripts.
Epigenetic reprogramming of cell fate with trichostatin A
(TSA)
Histone deacetylation has been implicated in modulating
OL lineage progression, particularly for developmental
species undergoing cell cycle exit and progressive stages
of cellular differentiation characterized by the acquisi-
tion of a branched morphology and the onset of myelin
gene expression [25]. Treatment with TSA, an HDAC
inhibitor, prevents progression of OLPs into PMOs with
the resulting preservation of a simplified morphological
phenotype that does not display secondary branching
characteristic of differentiating PMOs (Figure 3). The
inhibition of HDAC suppresses OL-specific gene expres-
sion and reprograms these cells into a less lineage com-
mitted state receptive to neurogenic or gliogenic
differentiation signals [22-24,26,78-81]. Given that we
observed a number of ncRNAs exhibiting specific
expression profiles during OL lineage progression, we
were interested to examine whether their expression
was similarly regulated by histone deacetylation.
Changes to ncRNA expression in response to HDAC
inhibition would suggest the incorporation of these
ncRNAs within a genetic program that contributes to
progression of either neuronal or oligodendrocyte
differentiation.
We employed QRT-PCR to examine the expression of
ncRNAs identified within this study as strong candidates
for functional roles in OL or neuronal differentiation.
Broadly, we found parallel changes in cellular phenotype
and alterations in ncRNA expression profiles induced by
TSA. In addition to examples described above, we
included other ncRNAs associated with neural develop-
mental genes that exhibited representative developmen-
tal expression profiles. Almost all selected ncRNAs (14
of 15) exhibited significant (p < 0.05) changes in expres-
sion at 24 or 48 h (Figure 3). The majority of these
changes were sustained or developed during later stages
(i.e., at 48 h), suggesting the expression of these ncRNAs
is subject to regulation by mechanisms of histone
deacetylation.
While we observed both increased and decreased
expression of long ncRNAs, the majority was downregu-
lated, often dramatically, supporting the putative role of
these ncRNAs in contributing to the progressive differ-
entiation of OLs (Figure 3). Downregulated ncRNAs
included those associated with protein-coding genes
involved in progressive OL differentiation. In addition to
those previously described including Sox8OT, Gomafu,
AK014263 (hosted in an intron of Csmd1) and
AK019302 (hosted in an intron of Bai3), we also
observed dramatic downregulation of ncRNA AK020939
which is hosted within an intron of Lhfpl3, a member of
the tetraspanin proteins which promote proliferation,
migration and differentiation of OLs [82,83].
Recent evidence has shown that histone deacetylation
is responsible for restricting neuronal gene expression,
with the inhibition of HDACs inducing neuronal differ-
entiation [84]. Therefore, it is of interest that a number
of candidate ncRNAs exhibit an increase in expression
in response to HDAC inhibition, possibly suggesting a
contribution to neuronal rather than OL differentiation.
For example, the previously described ncRNA Gtl2 was
upregulated after TSA treatment. Indeed, within his
study we observed upregulation of Gtl2 during GABAN
differentiation. Gtl2 is expressed in restricted domains
of the developing forebrain including ventral telencepha-
lon, neocortex, hippocampus and diencephalon, suggest-
ing roles in regional neuronal development and
differentiation [85]. Finally, we found that Neat1 tran-
scription exhibited complex transcriptional dynamics
after TSA treatment, being strongly upregulated after
TSA treatment under stochastic (probabilistic) oligoden-
droglial specification conditions, whereas it was downre-
gulated after TSA treatment under the influence of
instructive (inductive) signals for OL lineage elaboration
(see Methods; Figure 3 and Additional file 15).
Discussion
In this study, we utilized a custom-designed microarray
platform to probe the transcription of both protein-cod-
ing and noncoding transcripts during ventral forebrain-
derived NSC lineage restriction, neuronal and oligoden-
drocyte (OL) lineage specification, neuronal-glial fate
transitions, and progressive stages of OL lineage ela-
boration including myelination. Expression profiles for
mRNAs in our study were similar to previously reported
findings [62,86] showing modulation of key signaling
pathways, transcription factors, and epigenetic regulators
that help to define the molecular codes governing neural
lineage elaboration. Additionally, we also observed
expression of components of the myelin sheath.
Although we examined protein-coding genes, we
focused primarily on characterizing the expression pro-
files of long ncRNAs, which are being increasingly
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appreciated in the regulation of developmental gene
expression programs [3,4,7,28]. Previous studies of
neural differentiation have reported expression profiles
for only a small number of long ncRNAs, such as
Nkx2.2AS and the imprinted H19 ncRNA [62,86,87]. In
contrast, we examined a large spectrum of long ncRNAs
and found dramatic changes in expression that are
unique to specific stages of cellular differentiation. Many
of these ncRNAs are transcribed from complex genomic
loci that encompass protein-coding genes with defined
roles in neuronal and glial lineage elaboration, and these
pairs of ncRNAs and associated protein-coding genes
often exhibited coordinated expression during develop-
mental transitions. Therefore, we suggest that these
ncRNAs may influence the expression of the associated
protein-coding genes similar to previously characterized
examples such as Nkx2.2AS [87], HOTAIR [29], p15AS
[30], p21AS [15] and Evf2 [31]. For example, many
ncRNAs were associated with transcription factors that
were themselves differentially regulated during OL dif-
ferentiation [62,86]. Long ncRNAs, such as those
identified in this study, may therefore contribute to the
combinatorial transcriptional codes involved in lineage
specification and terminal differentiation including
myelination.
The coordinated expression of long ncRNAs with cri-
tical neural developmental protein coding genes suggests
that both are subject to shared regulatory mechanisms
and that long ncRNAs are integrated into complex
environmentally-mediated neural and glial developmen-
tal gene expression programs. We, therefore, considered
whether the well-documented ability of epigenetic
mechanisms to promote decisive changes in neuronal
and glial gene expression programs also includes the
capacity to regulate long ncRNA expression. Indeed,
treatment with the HDAC inhibitor, TSA, effectively
arrests the developmental progression of OLPs into
PMOs [23] and also affects the expression of long
ncRNAs, suggesting that these are not only regulated by
epigenetic modifications but also these transcripts are
incorporated into a broader lineage specific develop-
mental gene expression program. Furthermore, HDAC
Figure 3 The HDAC inhibitor, TSA prevents the acquisition of secondary morphological features of differentiating PMOs with
concurrent alteration in the expression profiles of ncRNAs. (A-D) Immunofluorescence micrographs demonstrating the profiles of OL lineage
species in the absence (A, B) or presence of TSA (C, D) at 24 h and 48 h. (E) The fold change in ncRNA expression in TSA treated versus
untreated PMOs at 24 h and 48 h. (F) The fold change in Neat1 expression in TSA treated versus untreated PMOs under CNTF presence
(instructive) or absence (stochastic) with concurrent PDGF-AA factor withdrawal. Immunofluorescence micrographs of CNTF naïve, TSA treated
cells and fold-change as determined by Q-PCR for remaining ncRNAs is illustrated in Additional file 15. (Error bars indicate standard error with
asterisks indicated significant fold change at p > 0.05).
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inhibition also has differential effects on certain ncRNAs
in an environmentally responsive manner. For example,
treatment of OLPs with TSA in the presence (inductive)
or absence (stochastic) of CNTF results in opposing
profiles of Neat1 expression, implying that long ncRNAs
might be deployed in a context-specific manner to dyna-
mically modulate seminal fate decisions within the OL
lineage. Although the use of HDAC inhibitors has been
essential for interrogating the epigenetic mechanisms
that govern OL lineage maturation, the cellular effects
of TSA administration are complex and our understand-
ing of the mechanisms mediating ncRNA expression are
still evolving. Nonetheless, long ncRNAs may represent
important targets for regenerative therapies in the CNS
because they exhibit both exquisite site-selective as well
as genome wide effects [5,13] associated with dynamic
OL developmental transition states characterized by
considerable epigenetic flux [22-24,26,78,79,81].
Conclusions
This study is the first systematic examination of the
expression of long ncRNAs in forebrain-mediated NSC
maturational processes, specifically OL differentiation
and development. It is also the first demonstration that
long ncRNAs, many of which are involved in regulating
epigenetic processes, are also themselves subject to reg-
ulation by epigenetic processes. It adds to a growing
consensus that not only are large portions of the mam-
malian genome transcribed [27] but also expressed in a
regulated manner [7]. The specific expression of
ncRNAs has been recently observed in other develop-
mental programs and comparisons between these stu-
dies reveal both common and unique features [7,88].
Because the long noncoding transcriptome is still rela-
tively poorly annotated and only partially interrogated
by this study, it seems likely that many more long
ncRNAs will be shown to be expressed during develop-
ment and their importance for neuronal and glial biol-
ogy will be more fully understood and appreciated.
These studies will have particular relevance in the future
as the role of noncoding transcripts in neurological dis-
ease states becomes increasingly recognized [89].
Methods
Neural stem cell cultures
Early embryonic (E14) multipotent and more lineage-
restricted progenitor species derived from the ventral
forebrain were plated at clonal density (1000 cells/mL)
and propagated in serum free media (SFM) containing
specified factors for various time intervals, and subse-
quently examined by immunofluorescence microscopy
to define neural lineage profiles, expression of selected
transcription factors (Figure 1) and to detect cellular
proliferation (BrdU, 10 μM, added 3 h prior to fixation)
as previously described [20,90-92]. Multipotent progeni-
tor clones were generated by application of basic fibro-
blast growth factor (bFGF, 10 ng/mL) and were cultured
7 days in vitro (DIV) and were passaged twice to enrich
the self-renewing NCSs. Subsequently, NSC clones were
dissociated by trypsinization and were exposed to bFGF
and the N-terminal active form of Shh (N-Shh, 50 ng/
ml) for 2 DIV to generate N/OP clones [20]. GABANs
were generated from N/OPs by the application of BMP2
(10 ng/mL) for 2 DIV. OLPs were generated from N/
OPs by the application of PDGF AA (10 ng/mL) for 4
DIV [Additional file 11] [20,71]. PMOs and MYOs were
generated from on 6 DIV late-stage OLPs by withdrawal
of PDGF and concurrent addition of CNTF (20 ng/mL)
for an additional 2 DIV and 4 DIV respectively [65,71].
We followed institutional IACUC guidelines for experi-
ments in which primary mouse tissue specimens were
used (Einstein Institute for Animal Studies protocol #
20080709).
Trichostatin A (TSA) treatment
The application of TSA (10 ng/mL, Sigma) to OLs was
done at the time of withdrawal of PDGF in the presence
(inductive oligodendrogliogenesis) or absence (stochastic
oligodendrogliogenesis) of CNTF that is necessary to
promote cell cycle exit and OL differentiation. In addi-
tion to study of the four developmental stages encom-
passing oligodendrogliogenesis (N/OPs ® OLPs ®
PMOs ® MYOs), we also analyzed the expression pat-
terns of selected ncRNAs at the time of PDGF withdra-
wal without CNTF or TSA addition (T0), and at 24 h
and 48 h after TSA treatment in the presence and
absence of CNTF [72,93]. We also compared these
values to data obtained from OLs not treated with TSA
at 24 h and at 48 h [25].
Immunofluorescence microscopic analysis
This analysis was performed as previously described
[72,93].
Antibody preparations
Antibodies against the neuroepithelial marker, nestin
(mIgG1, 1:200, Pharmingen) were used to label both
NSCs and N/OPs. N/OPs were distinguished from NSCs
by the expression of the bHLH factors, Olig2 (goat IgG,
1:500, R&D) and Mash1 (mouse, mIgG1, 1:250, Phar-
mingen). Progressive stages of OL lineage elaboration
were documented by the expression of the OL progeni-
tor marker, O4 (mIgM, 1:600 Sigma), the PMO marker,
GC/O1 (mIgM, 1:300 Chemicon) and the MYO marker,
MBP (mIgG2b, 1:500 Sternberger Monoclonals Inc.).
GABANs were identified by immunoreactivity against
GABA (rabbit IgG, 1:1000 Sigma). Expression of
PDGFRa on N/OPs was assessed using an antibody
Mercer et al. BMC Neuroscience 2010, 11:14
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against PDGFRa (goat IgG, 1:300, R&D Systems).
Nuclear and cell cycle-associated reagents (BrdU,
mIgG1, 1:400, Novocastra; Hoechst 33342, 2 μg/mL)
were utilized to assess cell proliferation.
Growth factors
To generate the various neural stem, progenitor and
more lineage-restricted neuronal and OL lineage species
required for immunocytochemical analysis, the following
growth factor preparations were utilized: recombinant
bFGF (Collaborative Biomedical Products), N-Shh,
PDGF-AA and CNTF (R&D Systems) and BMP2 (gift
from Genetics Institute).
RNA preparations
RNA from mouse tissues and cell cultures was purified
using Trizol (Invitrogen) or RNeasy Mini Kit (Qiagen)
and treated with DNase I (Invitrogen), according to the
protocols provided by the manufacturers. The quality of
purified total RNA samples was assessed with an RNA
6000 Nano assay kit using the Agilent 2100 Bioanalyzer
(Agilent Technologies) according to the manufacturer’s
instructions. For microarray experiments, RNA was
amplified and labeled using the Amino Allyl Message
Amp II kit (Ambion) following the instructions provided
by the manufacturer. Amplified aRNA from each time
point, as well as a reference pooled sample comprising a
mixture of RNA from all time points, was labeled with
either Cy3 or Cy5 monoreactive dyes (Amersham Bios-
ciences) according to the MessageAmp II protocol
(Ambion). The quality and quantity of amplified RNA
samples were assessed using the Agilent 2100 Bioanaly-
zer as described above.
Microarray expression profiling
The microarrays contained 22,038 65-mer oligonucleo-
tide probes from the Mouse OligoLibrary (Compugen,
San Jose, CA, USA) and 2,118 70-mer oligonucleotide
probes that were designed to target ncRNAs, including
known mouse pre-miRNAs from miRBase [94], longer
mouse ncRNAs from RNAdb [1], and “high confidence”
ncRNAs identified from the FANTOM3 project [1]. The
custom 70-mer probes were printed alongside Mouse
OligoLibrary probes on Power Matrix slides (Full Moon
BioSystems, Sunnyvale, CA, USA) at the SRC Microar-
ray Facility (University of Queensland, Brisbane, Austra-
lia). The quality of the print run was verified by
hybridizing random 10-mer oligonucleotides to the 1st
and last slides of the run. The array design is available
from the ArrayExpress Data Warehouse (EMBL-EBI;
ArrayExpress Accession Number A-MEXP-1070).
Labeled RNAs from each of the five developmental
stages was hybridized with the NSC sample to individual
microarrays. Three biological replicates were performed
for each time point. Blocking, hybridization and washing
was performed according to the manufacturer’s instruc-
tions (Full Moon BioSystems, Sunnyvale, CA, USA).
Slides were scanned at 5 μm resolution using a DNA
microarray scanner (Agilent Technologies). Feature
extraction was performed using ImaGene software (Bio-
Discovery, El Segundo, CA, USA), with manual grid
adjustment and auto-spot finding and segmentation.
Data was exported from ImaGene as text files, then
uploaded and analyzed using the Linear Models for
Microarray Data (LIMMA) software package via the R
Project for Statistical Computing http://www.r-project.
org. Data was background-corrected, normalized both
within and between arrays [95], and differential expres-
sion analysis was performed by fitting a linear model of
the data to the experimental design matrix and then cal-
culating Bayesian statistics (B statistics; posterior log
odds) adjusted for multiple testing using Benjamini-
Hochberg analysis [96]. Raw and processed microarray
data is available at the ArrayExpress Data Warehouse
(EMBL-EBI; ArrayExpress Accession Number E-TABM-
874).
PCR primers
The primers were designed and synthesized (Invitrogen)
to amplify selected ncRNA sequences [Additional file
16].
Quantitative real-time PCR
Quantitative real-time PCR (QRT-PCR) was performed
according to manufacturer’s protocols (Qiagen). QRT-
PCR reactions were performed in a 96-well plate, each
reaction consisted of a 25 μL mixture including 12.5 μL
of 2× QuantiFast SYBR Green PCR Master Mix (Qia-
gen), 1 μM of forward and reverse sequences of the cor-
responding primers and 40 ng of cDNA. Mouse 18S
ribosomal RNA was used as an internal control to
ensure accuracy of the results. QRT-PCR amplifications
were performed using the ABI PRISM 7000 Sequence
Detection System (Applied Biosystems). Amplification
conditions were as follows: 5 min at 95°C to activate the
HotStarTaq Plus DNA Polymerase followed by 40 cycles
of 10 s at 95°C and 30 s 60°C. QRT-PCR conditions
were optimized by adjusting the primer concentrations
and the quantity of cDNA. A dissociation curve was
performed to ensure the validity of each specific PCR
product. QRT-PCR results were analyzed using Relative
Expression Software Tool [97] software http://rest.gene-
quantification.info/.
Classification of probes targeting protein-coding or non-
protein-coding transcripts
Although the Mouse OligoLibrary probe set was predo-
minantly designed to recognize known or putative
Mercer et al. BMC Neuroscience 2010, 11:14
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protein-coding transcripts, several thousand probes tar-
geted miscellaneous cDNAs and ESTs whose coding sta-
tus was not well characterized at the time this
commercial probe set was first produced. To update the
annotation of these probes and to clarify whether they
targeted protein-coding or noncoding regions, a compu-
tational pipeline was designed to re-annotate the entire
probe set. Sequences for all probes were mapped to the
February 2006 (NCBI Build 36) assembly of the mouse
genome using BLAT [98] (parameters: minScore = 50,
minIdentity = 99, stepSize = 5, tileSize = 11, ooc = 11.
ooc). Probes that could not be reliably mapped were
excluded from the study. Targeted transcripts were then
defined as protein-coding and noncoding as described
previously [7]. The genomic context of ncRNAs (relative
to protein-coding genes) was also determined as
described previously [6].
Conservation and secondary structure predictions of
ncRNAs
The secondary structural composition of expressed
ncRNAs was determined by intersecting their chromo-
somal positions with those of the RNAz structural pre-
dictions made across the entire mouse genome (using
confidence threshold levels of P > 0.5 and P > 0.9),
which were performed as previously described [6,34].
High confidence predicted RNA secondary structures
were rendered with CONTRAfold [99].
Gene Ontology (GO) term and microRNA target
enrichment analysis
The Gene Ontology project http://www.geneontology.
org/ provides a controlled vocabulary to functionally
annotate genes. By studying GO terms associated with a
large set of genes, one obtains useful information about
the types of genes represented. Lists of differentially
expressed protein-coding genes were uploaded into Fas-
tiGO+ http://babelomics.bioinfo.cipf.es[100]. Statistically
over-represented GO terms in the biological process
and molecular function and microRNA target enrich-
ments were obtained by applying a p-value cutoff as
indicated, correcting for multiple testing with Benjamini
False Discovery Rate.
Additional file 1: Expression of mRNAs according to microarray
analysis at different stages of oligodendrocyte and neuronal
differentiation. Abbreviations are: bipotent progenitor cells, N/OP;
GABAergic neurons, GABAN; oligodendrocyte progenitors, OLP; post-
mitotic oligodendrocytes, PMO; myelinating oligodendrocytes: MYO).
Probe IDs for targeted mRNA may be queried in the NRED database
[102]. Information for targeted mRNAs shown includes Accession IDs,
UniGene Common Name and Symbol and M-statistic, Fold Change, A-
and B-statistic as calculated from microarray analysis.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S1.XLS ]
Additional file 2: Expression of ncRNAs according to microarray
analysis at different stages of oligodendrocyte and neuronal
differentiation. Abbreviations are: bipotent progenitor cells, N/OP;
GABAergic neurons, GABAN; oligodendrocyte progenitors, OLP; post-
mitotic oligodendrocytes, PMO; myelinating oligodendrocytes: MYO).
Probe IDs for targeted mRNA may be queried in the NRED database
[102]. Information for targeted ncRNAs shown includes Accession IDs, M-
statistic, Fold Change, A- and B-statistic as calculated from microarray
analysis.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S2.XLS ]
Additional file 3: QRT-PCR validation for microarray analysis of
ncRNA expression in OL lineage elaboration. QRT-PCR analysis was
performed to evaluate expression of 11 ncRNA across five cell types and
corroborated microarray data in 48 (87%) of 55 instances.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S3.XLS ]
Additional file 4: Noncoding RNAs associated with protein-coding
genes. Noncoding transcript accession IDs are shown with associated
protein-coding UniGene Common Name and Symbol and relationship of
association (intronic, bidirectional, antisense). Evidence for positional
conservation of ncRNA with homologous gene in the human genome
(hg18) indicated.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S4.XLS ]
Additional file 5: Noncoding RNA transcripts sequences predicted
to fold into high confidence (P > 0.9) secondary structures
according to RNAz. Chromosome coordinates and sequences are
provided for region of expressed ncRNAs that are predicted to fold into
conserved secondary structures. Predicted secondary structures according
are provided in dot-bracket annotation (analysis conducted with Vienna
RNA Package [101]). Selected high confidence structures are illustrated in
Additional file 6.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S5.XLS ]
Additional file 6: Rendered illustrations of the top five most stable
secondary predicted structures in expressed ncRNAs. The five most
predicted stable structures were rendered using CONTRAfold [99].
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S6.PDF ]
Additional file 7: Gomafu expression during GABAergic neuronal
and progressive stages of OL lineage elaboration. (A) Relative
expression of Gomafu during GABAN and OL differentiation (expression is
relative to NSCs and error bars show standard deviation). Gomafu is
exclusively downregulated in N/OPs, but upregulated in all other
sampled cell stages. (B) In situ hybridization of sagittal adult mouse brain
sections for Gomafu expression. Whole brain is shown in top left panel,
hippocampus top right panel, coronal section of olfactory bulb in
bottom left panel, and sagittal section of olfactory bulb and cortex in
bottom right panel. Gomafu is expressed in the cortex (green arrow),
hippocampus and mitral layer of the olfactory bulb (red arrow). Gomafu
does not exhibit expression in the cerebellum (blue arrow). Images
courtesy of the Allen Brain Atlas http://www.brain-map.org.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S7.PDF ]
Additional file 8: Snhg10 exhibits specific expression profiles in the
adult mouse brain. Snhg10 exhibits a strong and broad expression
throughout the whole mouse brain (A), with specific expression in
Purkinje cells in the cerebellum (B) and hippocampus (C). Images courtesy
of the Allen Brain Atlas http://www.brain-map.org.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S8.PDF ]
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Additional file 9: mRNAs and ncRNAs that exhibit discordant
expression trends during neuronal-glia fate switching. Table shows
probe IDs that may be queried in the NRED database (Dinger et al.,
2008), UniGene Common Name and Accession IDs and the discordant
M-statistic and fold change associated with neural stem cell to
GABAergic neuron (GABAN vs NSC) or oligodendrocyte progenitor (OLP
vs NSC) transition as determined by microarray analysis.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S9.XLS ]
Additional file 10: Expression of ncRNAs associated with
ultraconserved elements. (A) Genomic context of the Dlx1 and Dlx2
gene (dark blue), the ncRNA Dlx1AS (AK132348; red) showing the
position of ultraconserved element with previously described enhancer
function (VISTA 422; green) and histogram of vertebrate conservation
(dark blue). (B) Enhancer (VISTA 422) function driving reporter gene
expression in the developing forebrain (red arrow) of 11.5 day mouse
embryo [55]. Images courtesy of VISTA Enhancer Browser http://enhancer.
lbl.gov/frnt_page.shtml. (C) Expression of Dlx1AS (red) and Dlx1 gene
(blue) during OL differentiation (expression is relative to NSCs and error
bars show standard deviation). Dlx1AS ncRNA is upregulated in GABAN,
similar to Dlx1, but downregulated in N/OPs and in different stages of OL
differentiation (OLPs, PMOs, MYOs). (D) Genomic context of the Dlx5 and
Dlx6 genes (blue) and the ncRNA Evf transcripts (1 and 2; red) showing
the position of two ultraconserved elements with previously described
enhancer function (VISTA 298) [55] and the enhancer described by Feng
et al. [31]; green) and histogram of vertebrate conservation (dark blue).
(E) Enhancer (VISTA 298) function driving reporter gene expression in the
developing forebrain (red arrow) of 11.5 day mouse embryo [55]. Images
courtesy of VISTA Enhancer Browser http://enhancer.lbl.gov/frnt_page.
shtml. (F) Expression of Evf (red) and Dlx5 gene (blue) during
oligodendrogliogenesis (expression is relative to NSCs and error bars
show standard deviation). The Evf ncRNA (red) is upregulated during
GABAN, similar to Dlx5 (blue), but downregulated in N/OPs and later
stages of oligodendrogliogenesis (OLPs, PMOs, MYOs). (G) Genomic
context of the novel AK005755 ncRNA (red) showing the position of;
ultraconserved element with previously described enhancer function
(VISTA 433; green) and histogram of vertebrate conservation (dark blue).
(H) Enhancer (VISTA 433) function driving reporter gene expression in the
developing forebrain (red arrow) of 11.5 day mouse embryo [55]. Images
courtesy of VISTA Enhancer Browser http://enhancer.lbl.gov/frnt_page.
shtml.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S10.PDF ]
Additional file 11: Elaboration of PDGFRa on bipotent neuronal/
oligodendrocyte precursors (N/OPs) independent of PDGF-AA
application following propagation in vitro. N/OPs at 2 h (A-B) in vitro
express the bHLH transcription factors, Olig2 and Mash1 (A), in addition
to nestin (B). Immunofluorescence microscopic analysis reveals that
PDGFRa is not initially expressed by this cellular species in our clonal
culture paradigm. However, PDGFRa expression is unequivocally present
at 24 h (C-D, arrowheads), demonstrating that N/OPs begin to acquire
PDGFRa expression and responsiveness to PDGF-AA, which is required
for proliferation and migration of OL progenitors following specification.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S11.PDF ]
Additional file 12: Gene expression profiles of ncRNAs during
oligodendrocyte differentiation. Correlation of expression profiles of
ncRNAs with protein-coding gene markers during
oligodendrogliogenesis. Genes with well-characterized roles in
oligodendrogenesis were used to identify ncRNAs with correlated
expression profiles (Pearson’s coefficient > 0.9). This included Olig1 (A;
purple) and Stm2 (B; red) that are differentially expressed in OLPs or
Mobp (C; blue) or Melk (D; pink) that are differentially expressed during
terminal differentiation to MYOs. NcRNA accession IDs are available in
Additional file 13.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S12.PDF ]
Additional file 13: Noncoding RNAs that exhibit concordant
expression profiles with marker genes with well-characterized roles
in neuronal and oligodendrocyte differentiation. Genes with well-
characterized roles in oligodendrogliogenesis were used to identify
ncRNAs with correlated expression profiles (Pearson’s coefficient > 0.9).
These genes include Olig1, Stmn2, Mobp, Melk, MOG, Mash1 and Nkx2-2.
Illustration of selected expression profiles is shown in Additional file 13.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S13.XLS ]
Additional file 14: The Sox8 gene and associated Sox8OT ncRNA
share a dynamically modified chromatin domain. The genome
browser view shows the bidirectional organization of the Sox8 gene
(blue) and the Sox8OT ncRNA (red). A shared promoter region (shaded
box) exhibits dynamic chromatin remodeling in embryonic stem cells (A;
ES), embryonic fibroblasts (B; MEF) and neural progenitors (C; NP) [61].
The combination of active H3K4me3 (green histogram) and repressive
H3K27me3 (red histogram) modified chromatin, observed in ES and MEF
cells, is termed a bivalent domain and is indicative of a gene in a
‘poised’ state for activation. This is reflected in the low prevalence of
H3K36me3 modified chromatin (blue histogram) that is normally
associated with RNA Polymerase elongation. In NPs the bivalent domain
has been resolved to an active H3K4me3 domain and the presence of
H3K36me3 modified domains implies that both the Sox8 and Sox8OT
transcripts are concordantly upregulated. Tpm; tags per million.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S14.PDF ]
Additional file 15: The HDAC inhibitor TSA prevents the acquisition
of secondary morphological features of differentiating PMOs with
concurrent alteration in the expression profiles of ncRNAs under
instructive conditions (CNTF treatment) and stochastic (CNTF naïve)
for OL lineage maturation. (A-D) Immunofluorescence micrographs
demonstrating the profiles of OL lineage species in the absence (A, B) or
presence (C, D) of TSA at T1 (24 h, A, C) and T2 (48 h, B, D) in the
presence of CNTF with concurrent PDGF-AA factor withdrawal. (E, F) The
effects of TSA application on comparative expression profiles of ncRNAs
as assessed at T1 (E) and at T2 (F) in relation to the timing of TSA
exposure in the experimental conditions. (G-K) Immunofluorescence
micrographs demonstrating the profiles of OL lineage species in the
absence (G, H) or presence (J, K) of TSA at T1 (24 h, G, J) and T2 (48 h, H,
K) in the presence PDGF-AA factor withdrawal only. (L, M) The effects of
TSA application on comparative expression profiles of ncRNAs assessed
at T1 (L) and at T2 (M) in relation to the timing of TSA exposure in the
experimental conditions.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S15.PDF ]
Additional file 16: List of ncRNA primers used in the validation of
microarray results by QRT-PCR.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
14-S16.XLS ]
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